CONTEXT

Osteoporosis based on age and various osteolytic diseases such as rheumatoid arthritis and bone metastasis of breast tumors are diseases accompanied by local or systemic degeneration of bone tissue. These pathologies result in an effect and excessive differentiation of osteoclasts, cells specialized in bone resorption. It is a major public health problem that affects hundreds of thousands of people worldwide. The prevention of these osteolytic diseases that generate chronic pain and impotence has become a key social and economical priority. Treatments exist, but their efficacy is partial and they have side effects. Therefore, it is important to understand the mechanisms by which osteoclasts are activated in these disease states, and to devise rational and therapeutic means to inhibit or reduce this activation.